# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer ra...
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older w...
HC Wainwright & Co. analyst Yi Chen reiterates Regenxbio (NASDAQ:RGNX) with a Buy and maintains $38 price target.
Aligned with FDA on content of BLA and plans for submission: Submission of a rolling BLA using the accelerated approval p...
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.